Kiromic BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, net loss was USD 12.06 million compared to USD 15.8 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | +11.59% | +27.80% | +254.02% |
10/05 | Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
01/05 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+254.02% | 35.56L | |
+8.05% | 11TCr | |
+10.21% | 11TCr | |
+0.41% | 2.23TCr | |
-12.15% | 2.22TCr | |
-5.99% | 1.94TCr | |
-37.36% | 1.79TCr | |
-6.30% | 1.72TCr | |
+7.35% | 1.43TCr | |
+36.73% | 1.25TCr |